Parexel Outlines Biopharma Advances And Increased Outsourcing
This article was originally published in The Pink Sheet Daily
Executive Summary
The CRO highlighted industry R&D success and an ever-expanding reliance on outsourcing at its June 26 investor day. Management said there are already more clinical development staff at CROs than within biopharma and suggested that soon more drug development will be done by CROs than drug manufacturers.